Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jennifer Skeen, David Goldstein, Robert Shovlin, More

Premium

Pathway Genomics has tapped Jennifer Skeen to serve as VP of clinical operations. Skeen recently was the laboratory director at Asuragen, and she has more than 20 years of experience in the diagnostics and biotech industries in the US and abroad.


David Goldstein will join Columbia University as director of a new Institute for Genomic Medicine, which will be a partnership with New York-Presbyterian, and as a professor of genetics and development in the College of Physicians and Surgeons at the beginning of 2015.

He will be responsible for building a program that integrates genetics and genomics into research, patient care, and education at Columbia University Medical Center and New York-Presbyterian, and developing programs to prepare students for careers in genomics and personalized medicine. Goldstein also will have a faculty appointment at the New York Genome Center and an appointment in neurology at Columbia's College of Physicians and Surgeons.

Goldstein joins Columbia from Duke University, where he has been director of the Center for Human Genome Variation and a professor with appointments in molecular genetics and microbiology. His research has focused on identifying relationships between human genetic variations and a range of diseases.


NeoGenomics has appointed Robert Shovlin as chief operating officer, effective Oct. 13. He was chief development officer for Bostwick Laboratories where he was responsible for sales, marketing, managed care, business development, and clinical trials. Before that, he held several positions at Aureon Biosciences, including president and CEO. Shovlin was also executive director for anatomic pathology and director of managed care for Quest Diagnostics.


Quest Diagnostics announced that Franklin Cockerill, III, is its new VP and chief laboratory officer as of Oct. 1. Cockerill was most recently CEO of Mayo Medical Laboratories and served as the chair of laboratory medicine and pathology for the Mayo Clinic. He has held several leadership positions, including chairing the Microbiology Devices Panel of the US Food and Drug Administration's Medical Devices Advisory Committee; serving as an editor of the Journal of Clinical Microbiology; and serving as a program chair and board member of the Association for Molecular Pathology.

At Quest, Cockerill will oversee Quest's lab network and lead the firm's medical affairs strategies, and academic and government collaborations. He will replace Stephen Suffin, who is retiring at the end of the year, but will continue to consult through 2015.


Cypher Genomics said that it has appointed J. Patrick Ravenel to serve as its new chief technology officer. He previously served as VP of software development at MedImpact Healthcare Systems.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.